Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02654132Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2016
- Primary completion
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of elotuzumab in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Started Mar 2016; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02654132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654132.